Regeneron Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $925
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,300 From $1,082, Outperform Rating Maintained
Regeneron Pharmaceuticals Analyst Ratings
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183
Regeneron Pharmaceuticals Analyst Ratings
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050
Buy Rating for Regeneron Pharmaceuticals Amidst EU Approval of Dupixent and Positive Market Outlook
Regeneron Pharmaceuticals Analyst Ratings
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,060, Buy Rating Maintained
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,050
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
Regeneron Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Jefferies Raises Regeneron Pharmaceuticals' Price Target to $1,125 From $1,115
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,000.25